Share on StockTwits

Investment analysts at Stifel Nicolaus dropped their target price on shares of Conatus Pharmaceuticals (NASDAQ:CNAT) from $14.00 to $13.00 in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 67.10% from the company’s current price.

Separately, analysts at Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, June 13th. They set a “buy” rating and a $19.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $16.00.

Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 7.78 on Thursday. Conatus Pharmaceuticals has a one year low of $5.06 and a one year high of $15.67. The stock has a 50-day moving average of $7.89 and a 200-day moving average of $8.22. The company’s market cap is $120.0 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.06. Analysts expect that Conatus Pharmaceuticals will post $-1.66 EPS for the current fiscal year.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of medicines to treat liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.